Gold nanoparticle-based theranostics: disease diagnostics and treatment using a single nanomaterial

This article was published in the following Dove Press journal:
Nanobiosensors in Disease Diagnosis
5 May 2015
Number of times this article has been viewed

Abstract: Nanotheranostics takes advantage of nanotechnology-based systems in order to diagnose and treat a specific disease. This approach is particularly relevant for personalized medicine, allowing the detection of a disease at an early stage, to direct a suitable therapy toward the target tissue based on the molecular profile of the altered phenotype, subsequently facilitating disease monitoring and following treatment. A tailored strategy also enables to reduce the off-target effects associated with universal treatments and improve the safety profile of a given treatment. The unique optical properties of gold nanoparticles, their ease of surface modification, and high surface-volume ratio have made them central players in this area. By combining imaging, targeting, and therapeutic agents in a single vehicle, these nanoconjugates are (ought to be) an important tool in the clinics. In this review, the multifunctionality of gold nanoparticles as theranostics agents will be highlighted, as well as the requirements before the translation of these nanoplatorms into routine clinical practice.

Keywords: nanotheranostics, nanomaterials, gold nanoparticle, theranostics, cancer, nanomedicine

Introduction
Theranostics is aimed toward the development of platforms capable of combining diagnostic and therapeutic agents.1,2 These innovative systems combined into single platforms should help overcome the troublesome differences in biodistribution and specificity of imaging molecules and therapeutic drugs.3,4 Theranostic approaches have been proposed for the management of several diseases/disorders, in particular for cancer diagnostics and therapeutics. Cancer therapy greatly relies on chemotherapy and radiotherapy in which most anticancer drugs are essentially taken up by cells with high proliferative rate, a characteristic of cancer cells. However, extensive proliferation is not exclusive for tumor cells, and normal tissue also suffers from chemotherapeutic action, leading to severe side effects.5–7 The efficacy of conventional therapies is also often limited by the natural tendency of cells to evade therapy through mutational events that lead to multidrug resistance, poor drug penetration into tumor tissues, and serious damage to normal tissues.8–10

Conventional therapy toward heterogeneous diseases is rarely targeted directly toward a specific cell type or tissue. In fact, the administration of a specific treatment to a subpopulation of patients in accordance to their molecular profile and risk of adverse effects is believed to be a more effective clinical model for improved patient outcome. By selecting patients for targeted clinical trials, based on biomarker
identification, personalized medicine is expected to reduce health costs caused by unnecessary treatment.

To overcome these issues, alternative strategies have been proposed in which nanomedicine plays a key role, such as for innovative drug delivery systems that increase the bioavailability and concentration of anticancer drugs at target site, resulting in improved therapeutic index.\textsuperscript{6,7,11} Combination of diagnostic and therapeutic entities into a single delivery vector using nanotechnology – nanotheranostics – constitutes a step forward for tailored early disease detection, medical treatment, and disease prevention.\textsuperscript{12,13} These nanoformulations must ascertain whether an individual carries a specific disease biomarker and release the appropriate therapeutic dose in a kinetically regulated manner. The design of such a system ought to include the possibility of targeted delivery\textsuperscript{14,15} (to minimize off-target accumulation and, therefore, minimize side effects), and the release of the imaging/therapeutic molecule should be precisely triggered in the specific cellular environment.\textsuperscript{16,17} The developed platform should allow a combination of different effector molecules (eg, stabilizer, therapeutic agent, targeting and imaging moieties) for maximization of theranostic effect.\textsuperscript{18,19}

Here, we shall address options for surface functionalization of gold nanoparticles (AuNPs) toward therapy (section “Surface functionalization of AuNPs toward therapy”), and focus on the use of AuNPs as theranostic agents, ie, imaging purposes (section “AuNPs for imaging purposes”) and therapy, eg, from drug and gene delivery vehicles to photothermal ablation agents (section “Gold nanoparticles: from conventional drug and gene delivery vehicles to photothermal ablation agents”). Current trends relating to the translation of theranostic nanomaterials from the laboratory to the clinics shall be discussed in section “Theranostic nanomaterials: from the laboratory to the clinics?”.

Several nanotheranostics platforms have been presented over the past decade, namely, metal and silica nanoparticles (NPs), liposomes, and composite NPs (Table 1).\textsuperscript{6,11,20,21} These platforms allow visualization and monitoring of the route taken by the formulation, providing information about delivery kinetics, intra-organ and/or intratumor distribution, and drug efficacy. Using a single NP, it is possible to tune therapy while simultaneously providing for real-time monitoring of disease progression.\textsuperscript{1,22} Traditional methodologies such as X-ray computed tomography (CT) and magnetic resonance imaging (MRI) do not display sufficient sensitivity to diagnose the asymptomatic phases of a disease,\textsuperscript{23,24} and owing to current levels of sensitivity, numerous patients entail extended unnecessary treatments. A theranostic strategy might allow treatment termination once the biomarker levels are undetectable.

AuNPs have great potential to be explored as a multifunctional tool for a wide range of biological applications.\textsuperscript{25–27} Their unique optical properties make them excellent non-invasive imaging agents, adding to their high surface-to-volume ratio that allows them to be loaded with a plethora of molecules, such as targeting/imaging moieties and therapeutic agents (Figure 1). By integrating targeting, diagnostics, treatment, and monitoring, AuNPs overcome several constraints associated with conventional methods of diagnostics and treatment, ensuring the codeelivery of imaging and therapeutic molecules at the same site, with real-time monitoring of their effects.\textsuperscript{14,16,28} Also, targeted molecular imaging and delivery of the therapeutic moiety, with enhanced retention at the target sites, allow reduction of the nanoconjugate concentrations in circulation and therefore reduce systemic toxicity.\textsuperscript{19,29}

AuNPs may work as a multimodal imaging tool by loading them with two or more contrast agents (fluorophores, MRI agents, photoacoustic agents, surface-enhanced Raman spectroscopy [SERS] reporters) to improve disease characterization and avoiding a repeated challenge on the patient immune system.\textsuperscript{30} This is also valid for therapeutic agents: one can take advantage of the synergistic effects of different treatments (effective drug, photothermal therapy, and/or antisense DNA) by combining them onto a single AuNP.

This review will focus on nanotheranostics using a single agent, addressing specifically AuNPs, the need for this new model, and its advantages over conventional methodologies. A long way has been paved since the first theranostic agent – radiopharmaceutical iodine – was used for thyroid disease in the 1940s.\textsuperscript{31} We are now facing clinical trials of AuNPs for treatment of solid tumors: Aurimune® (PEGylated colloidal gold particles; Phase I) (CytImmune Sciences, Rockville, MD, USA) and AuroLase® (gold nanoshell; Phase I) (Nanospheres Biosciences, Inc., Houston, TX, USA). We will also address some bottlenecks that still need to be circumvented before the most promising agents can be effectively translated to the clinical practice, eg, in vivo efficacy, stability, and toxicity.

**Surface functionalization of AuNPs toward therapy**

The chemical functionality and reactivity of AuNPs may be customized through surface functionalization, which modulates the solubility, stability, charge effect of the nanocomplex, and interaction with other molecules.\textsuperscript{14,32–36} One of the most used approaches has been the use of thiolated biomolecules to easily functionalize the particle surface.\textsuperscript{33,37} Such plasticity allows the modification and design of the AuNPs’
surface chemistry, thus granting control over the circulation half-time and systemic clearance of these structures in the body,\(^\text{38}\) and allows the modification and tailoring of bioavailability, immunogenicity, and preferential accumulation site.\(^\text{39}\) There is a wide range of stabilizers available, such as thiolated biomolecules, polymers, dendrimers, phosphine, that may simultaneously act as therapeutic moieties (eg, microRNA, DNA, peptides, and antibodies). Polyethylene glycol (PEG) is one of the most widely used stabilizer molecules able to increase AuNPs’ circulation half-life and cellular uptake, with

<table>
<thead>
<tr>
<th>Type of nanoparticle</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesoporous silica NPs</td>
<td>Large surface area, Stability, Biocompatibility, Controllable porosity, Surface reactivity and ease of functionalization, Biodegradability</td>
<td>In vivo toxicity</td>
</tr>
<tr>
<td>Magnetic NPs</td>
<td>Large surface area, Small size allows longer circulation and tissue penetration, Controlled clustering, Multimodal applications (targeting, diagnostics, and therapy)</td>
<td>Poor colloidal stability, Limited biocompatibility and cytotoxicity, Nonbiodegradability</td>
</tr>
<tr>
<td>Gold NPs</td>
<td>Large surface area, Low hydrodynamic mean size, Multimodal applications (targeting, diagnostics, and therapy), Suitable for photodynamic therapy, Scaffold for additional agents, Ease of surface modification, Stability and biocompatibility</td>
<td>High costs for large-scale production, Lack of standard protocols for translation into the clinics, Nonbiodegradability</td>
</tr>
<tr>
<td>Liposomes</td>
<td>Flexibility of synthesis, modification, and formulation, Ease of conjugation and functionalization with targeting, contrast agents, probes, and fluorophores, Rapid cellular uptake and well-characterized cell internalization mechanism, Controlled release, Scaffold for additional agents, Low immunogenicity, Biocompatibility, Commercially available products</td>
<td>Low drug-loading efficiency, Batch-to-batch variation in manufacturing, High production cost, Limited instability and leakage of loaded materials, Low solubility, Rapid clearance</td>
</tr>
<tr>
<td>Dendrimers</td>
<td>Very precise size and shape controllability, Water solubility and biocompatibility, Elicit negligible immune response, Easy electrostatic interaction with nucleic acids</td>
<td>Nonspecific cytotoxicity, Limited release of the associated bioactives, Rapid clearance</td>
</tr>
<tr>
<td>Hydrogels</td>
<td>Selective surface modification, High degree of porosity and high loading capacity, Controlled and sustained release into target tissues, Biocompatibility and biodegradability</td>
<td>High production cost, Instability</td>
</tr>
<tr>
<td>Quantum dots</td>
<td>High photo- and chemical stability, Size- and structure-based tunable emission, High molar extinction coefficient, Low hydrodynamic mean size, Scaffold for additional agents, Potential for synergistic application in diagnostics and therapeutic applications, Suitable for photodynamic therapy</td>
<td>Toxicity, Difficult surface modification (thiol groups), Particle aggregation, degradation, and removal</td>
</tr>
<tr>
<td>Carbon nanotubes</td>
<td>Large surface area, Ultrahigh functionalization and loading capacities, High penetration capacity to biological barriers, Scaffold for additional agents, Imaging probe on its own with high spatial resolution, Suitable for photodynamic therapy</td>
<td>Nonbiodegradable, Toxicity (oxidative stress), Lack of a standard protocol to prepare high-purity carbon nanotubes in large scale</td>
</tr>
</tbody>
</table>

Note: Adapted with permission from Draz M, Fang B, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. \(\text{Theranostics.}~\text{2014;4(9):1023–1030.}\)\(^\text{12}\)

Abbreviation: NPs, nanoparticles.
Examples of Direct coupling
Homo-bifunctional thiolated PeG or Thiol
Carboxylic/phosphate

Thiolated DNA
Thiol/maleimide – Maleimide/thiol

Table 2 Common covalent immobilization strategies for AuNP functionalization

<table>
<thead>
<tr>
<th>Coupling reaction</th>
<th>Functional group at AuNP surface</th>
<th>Functional group on ligand</th>
<th>Linkers/spacers</th>
<th>Examples of biomolecules coupled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiol</td>
<td>Direct coupling</td>
<td>Thiol</td>
<td>–</td>
<td>Thiolated DNA 28,54</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thiolated PEG 46</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thiolated fluorophores</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Proteins 17</td>
</tr>
<tr>
<td>EDC/NHS</td>
<td>Carboxylic/phosphate or amine</td>
<td>Amine or carboxylic/phosphate</td>
<td>Bifunctional PEG/DNA chain harboring a thiol and a(n) amine/carboxylic group</td>
<td>Antibodies 14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fluorophores 118</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Peptides 119</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNA 20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chemotherapeutic agents 21</td>
</tr>
</tbody>
</table>

Abbreviations: AuNP, gold nanoparticle; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; NHS, N-hydroxysuccinimide; PEG, polyethylene glycol.

Gold nanoparticles as theranostic agents

Smartly designed NPs have already made their way to the clinics, eg, Doxil® (Janssen Biotech Inc, Horsham, PA, USA), Abraxane® (Celgene Corporation, Berkeley Heights, NJ, USA) – therapeutic application; Resovis® (Bayer Schering Pharma AG, Berlin, Germany) and Feridex® (Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA) – imaging agents, but the development of an equivalent able to combine both strategies is still underway. Indeed, several platforms have already been proposed integrating therapeutic strategies (ie, chemo-, genetic-, immunotherapy, photothermal ablation) and imaging agents to monitor NP fate, eg, MRI, CT, and photoacoustic tomography (PAT).48–50

Nanomaterials, such as AuNPs, exhibit remarkably different properties from the bulk material. Owing to the spatial confinement of the conduction electrons, unique optical properties arise (localized surface plasmon resonance [LSPR]) with strong impact on sensing and therapeutic applications.51–54 The intensity and frequency at which the LSPR occurs may be tailored through the variation of the metal composition, size, shape, and the dielectric surrounding.55,56 The light extinction induced by the LSPR...
comprises both absorption and scattering processes. The scattering component of the extinction band is proportional to the particle size, while the absorption component is inversely proportional to the particle size. AuNPs’ spectral behavior may also be explored in other regions of the spectrum. When an AuNP absorbs light, it can decay (in a nonradiative manner) to a lower energy level through the generation of heat. This particular phenomenon can be applied in photothermal therapy. Not only the LSPR is highly tunable, but also its extinction coefficient for laser absorption can be five orders of magnitude higher than those of conventional organic dyes used in photothermal absorption can be five orders of magnitude higher than those of conventional organic dyes used in photothermal procedures. Moreover, AuNPs are known to be resistant to photobleaching.

Although in an early stage of technological development, AuNPs-based diagnostic and therapeutic approaches have already been proposed to carry a drug or imaging agents directly targeted to a specific tissue and/or cell type. Generally, particulates between 10 nm and 60 nm in diameter tend to passively accumulate in tumor tissues due to the enhanced permeability and retention (EPR). EPR occurs due to changes to tumors’ endothelia, where the leaky vasculature allows extravasation of NPs to the extracellular milieu and decreased lymphatic drainage results in local accumulation. Yet, although NPs tend to naturally accumulate in tumors, functionalization allows proper recognition of selective cellular target – active targeting.

AuNPs for imaging purposes

AuNPs are extremely versatile since they may act as an imaging probe on their own and/or be easily functionalized with suitable imaging agent, overcoming some of the technique’s limitations. In fact, the idea of using multiple modalities has become popular, and recently, hybrid imaging instruments have become available, with the first to appear being a fusion of positron emission tomography (PET)/CT instrument, followed by PET/MRI, and, more recently, ultrasound/CT. These techniques may clearly benefit from multimodality, since a single agent could avoid the administration of multiple doses. The choice of imaging modality must be carefully considered since each one has its own advantages and limitations – eg, modalities with the highest sensitivity have relatively poor resolution. Improvement in these systems might allow the observation of tissues not only on its basic anatomic configuration but also on the molecular level. Moreover, real-time noninvasive monitoring of theranostic NPs enables a rapid decision on whether the treatment regimen is effective in a given patient. Herein, the focus shall be on AuNPs, and for further insights into other systems, please refer to additional reading.

AuNPs as fluorescence modulators

AuNPs and other noble metal NPs are known to modulate fluorescence of fluorophores in their vicinity, including quenching due to energy transfer or charge transfer. As the distance between a NP and a fluorophore increases, quenching by the NP decreases. Modulation of fluorescence has been used for the development of biosensing approaches and tracking of nanoformulations in living systems. One such example suitable for theranostics is the so-called gold nanobeacons (Au nanobeacons), ie, AuNPs functionalized with an effector ssDNA in a hairpin configuration tagged with a suitable fluorophore. Upon hybridization to the specific target (eg, mRNA or miRNA), the hairpin opens, quenching by the AuNP ceases to exert its influence, and fluorescence is observed, thus allowing to track the silencing effect within cells and tissues. This simple nanotheranostics platform may be easily applied to any RNA sequence (Figure 2).

Traditional fluorophore quenching may be substituted by SERS. In fact, noble metal NPs, such as gold and silver, are known to promote SERS of adsorbed dyes on NP surfaces, which has been widely used for biosensing in complex media.

These optical properties (high extinction coefficient with possibility of heat generation or scattered light, fluorescence modulation, and SERS) may be explored in a wide range of theranostics applications, which may also profit from the ease of AuNP surface modification with no observable toxicity.

Computed tomography and magnetic resonance imaging

CT is often the first approach for the detection of the region of pathology within tissues and organs. As for MRI, CT does not have the needed sensitivity to target molecular events or even to diagnose abnormal cellular events, which require contrast agents, such as gadolinium (Gd) in MRI and iodine contrast in CT. Although routinely used in the clinics, iodinated and Gd-based (to a lower extent) contrast agents exhibit side effects, namely, CT-associated life-threatening contrast-induced nephropathy and MRI-associated nephrogenic systemic fibrosis. For instance, contrast enhancement in CT is usually based on low-molecular-weight compounds that show rapid clearance, whereas AuNPs appear as an interesting alternative. In fact, acetylated dendrimer-entrapped gold nanoparticles (AuDENPs) were used for...
in vitro and in vivo CT imaging of a human lung adenocarcinoma cell line (SPC-A1 cells). Intratumoral and intraperitoneal administration of acetylated AuDENPs allowed the detection of cancer cells under X-ray in xenograft tumor models. In vitro assays show that acetylated AuDENPs are biocompatible and do not affect cell viability, making them good CT contrast agents.

Effective examples of AuNPs for MRI analysis include an innovative vector for improving MRI contrast agents currently used for clinical diagnosis. Moreover, Gd-loaded AuDENPs can be used for dual-mode CT/MRI. For instance, Alric et al functionalyzed AuNPs with diethylenetriaminepentaacetic acid (DTPA) to chelate Gd ions (Gd$^{3+}$). A total of 50 Gd ions per particle increases the system’s stability, allowing the application as contrast agent for both MRI and X-ray CT in vivo. Owing to their size, these nanoconjugates can also be used as sensitizers for radiotherapy.

Similarly, nanoconjugates formed by silica layer-coated gold nanorods to which folic acid (FA) was covalently anchored (AuNR-SiO$_2$-FA) were shown to be selectively taken up by MGC803 cells, subsequently enhancing their sensitivity to X-ray radiation. This way, these particulates may become a good candidate for X-ray CT imaging associated to tumor targeting. These same nanoconjugates could be eventually used for photothermal therapy.

Another example is the Co@Pt-AuNP platform that presents strong magnetism and high stability, resulting in a good MRI contrast agent to monitor the progression of A$\beta$ protofibrils involved in Alzheimer’s.

**Photoacoustic tomography**

AuNPs may also be used in PAT, a noninvasive modality combining high sensitivity of optical imaging with high resolution of ultrasound imaging. Contrast agents for PAT are photoabsorbing agents that, when excited at their resonance wavelength, convert light into heat (photothermal conversion) correlated to the generation of acoustic waves (due to thermoelastic expansion), which can then be detected by an ultrasound transducer. PAT has been slowly overcoming the limited resolutions of techniques dependent solely on ultrasonic diffraction. When used in the NIR of the spectrum, PAT is not constrained by the optical diffusion limit, which allows the reconstruction of images with improved spatial resolution, deep penetration depth, and excellent image contrast when compared to conventional optical imaging. Gold nanorods, due to their cylindrical shape, present characteristic SPR toward the NIR, and are of extreme use for PAT. PAT molecular imaging in deep tissue has also been improved by using reporter-gene products. Recently, Taruttis et al demonstrated real-time imaging of siRNA in
Gold nanoparticles: from conventional drug and gene delivery vehicles to photothermal ablation agents

AuNPs’ high surface area makes them proper systems for efficient vectorization of high payloads of drugs, including siRNAs or microRNAs. A wide range of molecules may be used for active targeting toward effective nanotheranostics, from hormones to cytokines, antibodies, and peptides (Table 3).

Another efficient way to reduce side effects is via systems that release their payload in a unique environment, as response to either internal or external stimuli – smart agents (triggered release). These systems may respond to changes in the pH or even to specific protease activity within the tumor surroundings. However, owing to AuNPs’ intrinsic characteristics, light and heat have been the most commonly explored actuator of drug release. As mentioned earlier, when AuNPs absorb light, it can be dissipated as heat, which may be used for the controlled release of drugs functionalized or adsorbed to the AuNPs’ surface.

In addition, the photothermal effect might increase blood perfusion in the tumor region, further increasing the delivery of therapeutics. AuNPs’ shape and size can be tuned at will (eg, nanospheres, nanorods, nanocages, or nanoshells), whose spectral behavior is directly correlated with a shift in the LSPR to the NIR region (650–900 nm), thus allowing deeper tissue penetration of light. Indeed, AuNP-mediated hyperthermia shows particular promise in animal studies, and early clinical testing is currently underway.

Combination of imaging platforms with hyperthermia is currently being developed in which a single particle is used to image tumors and later accurately and efficiently ablate them. Yushen et al developed a microparticle of AuNP-poly(lactic acid) with surface deposition of graphene oxide. The assembly was used for in vivo NIR photothermal therapy, suitable as contrast agent for both ultrasound and CT imaging. Together, AuNPs and graphene oxide coating allowed improved photothermal conversion, with the final outcome being total tumor remission due to the performed laser ablation treatment. However, the challenge of using gold nanorods in this type of therapy is the observation that after an intense and prolonged period under laser illumination, gold nanorods might lose stability, being reshaped to gold nanospheres, thus losing response to NIR frequencies.

Although gold nanorods tend to be considered the “gold standard” in photothermal therapy, colloidal gold nanoparticles have more frequently been used as theranostic agents. Their main disadvantage is the absorbance peak, situated in the visible region, whereas the low toxicity of nanospheres is one of the biggest advantages, since geometry plays a considerable role in acute cell toxicity. Hyperthermia success of AuNPs is determined by several factors, namely, sufficient depth penetration (up to 1 cm in the NIR) and low energy absorption by healthy tissues (to reduce collateral damage). For example, Melancon et al conjugated hollow gold nanospheres (HAuNS) displaying an average diameter of 30 nm with cetuximab (CET), an antiepidermal growth factor receptor (EGFR) therapeutic antibody. CET-HAuNS selectively bound to cells overexpressing EGFR (A431 cells) that, upon irradiation with NIR laser, led to elevation of temperature, inducing cell death by photothermal ablation. Moreover, labeling of HAuNS with gamma emitter. In allowed monitoring tissue distribution of CET-HAuNS in vivo, revealing increased uptake in tumors expressing EGFR.

SERS has also been used for tracking these multimodal NPs. Of particular interest is the work presented by Song et al in which an amphiphilic AuNP was coated with a Raman reporter BGLA (2-(4-(bis(4-(diethylamino)phenyl)(hydroxy)methyl)phenoxy)ethyl 5-(1,2-dithio-lan-3-yl)pentanoate). The particle was made stealth by PEG incorporation and pH-sensitive (due to PMMAVP grafts – hydrophobic copolymer of methyl methacrylate [MMA] and 4-vinylpyridine [4VP]). DOX was also included in this intricate system. Incorporation of HER2 antibody provided for specific targeting. Cellular binding, uptake, and intraorganelle disruption of the SERS-encoded pH-sensitive plasmonic vesicles were assessed. This unique system is an example of a promising platform for targeted theranostic applications of AuNPs.

Theranostic nanomaterials: from the laboratory to the clinics?

One of the first agents developed as a simultaneous targeting moiety and therapeutic agent was Herceptin (trastuzumab; Hoffman-La Roche Ltd, Basel, Switzerland), a humanized antibody capable of targeting and blocking the overexpression of HER2 protein used for the treatment of HER2-positive metastatic breast cancer. Similar approaches have followed, but most failed to deliver due to stand-alone limitations of these agents. Such failures have increased the costs of R&D without corresponding delivery to the market. As seen earlier, recent advances in nanotechnology have paved the way for the development of theranostics...
Table 3 Types of theranostic agents using AuNPs: their sizes, detection method, and therapeutic effect

<table>
<thead>
<tr>
<th>Nanoconjugate</th>
<th>Therapeutic agent</th>
<th>Type of nanoparticle</th>
<th>Particle size</th>
<th>Imaging</th>
<th>Therapy</th>
<th>Short description</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTX@PEG-AuNP</td>
<td>Paclitaxel</td>
<td>Nanospheres</td>
<td>20–40 nm</td>
<td>Fluorescence (Rrhodamine B)</td>
<td>Drug delivery</td>
<td>PEG@AuNPs, PTX, and rhodamine B linked beta-cyclodextrin for theranostics in vitro. PTX is released using intracellular glutathione.</td>
<td>50</td>
</tr>
<tr>
<td>DOX–PSMA–AuNP</td>
<td>Doxorubicin</td>
<td>Nanospheres</td>
<td>65 nm</td>
<td>X-ray CT</td>
<td>Chemotherapy</td>
<td>RNA aptamers bind PSMA, allowing specific imaging of prostate cancer cells expressing PSMA.</td>
<td>122</td>
</tr>
<tr>
<td>Au@DTDTPA-Gd</td>
<td></td>
<td>Nanospheres</td>
<td>2.4 nm</td>
<td>MRI, X-ray CT</td>
<td>Radiotherapy</td>
<td>Easy detection of Au@DTDTPA-Gd by MRI and X-ray CT; radiosensitizer for radiotherapy.</td>
<td>72</td>
</tr>
<tr>
<td>Au@PLA-(PAH/GO)</td>
<td></td>
<td>Spherical microcapsules</td>
<td>1.5 μm</td>
<td>US, X-ray CT</td>
<td>PTT</td>
<td>Contrast agent to simultaneously perform US and X-ray CT, both in vivo and in vitro.</td>
<td>73</td>
</tr>
<tr>
<td>CET-HAuNS</td>
<td>Cetuximab</td>
<td>Hollow nanospheres</td>
<td>35 nm</td>
<td>PET, PAT</td>
<td>Photothermal ablation</td>
<td>Excellent colloidal stability, high absorption coefficient and efficient photothermal effect in NIR.</td>
<td>91,97</td>
</tr>
<tr>
<td>AuNS</td>
<td></td>
<td>Nanoshell microcapsules</td>
<td>2.3 μm</td>
<td>US</td>
<td>PTT</td>
<td>AuNS can induce photothermal ablation of HeLa cells via exposure in NIR.</td>
<td>123</td>
</tr>
<tr>
<td>DOX@PEG-HAuNS</td>
<td>Doxorubicin</td>
<td>Hollow nanospheres</td>
<td>52 nm</td>
<td>PET, optical imaging</td>
<td>Thermal ablation, drug release</td>
<td>DOX released by photothermal conversion.</td>
<td>45,91</td>
</tr>
<tr>
<td>SPIO@AuNS</td>
<td></td>
<td>Nanoshell</td>
<td>80–90 nm</td>
<td>MRI</td>
<td>PTT</td>
<td>Superparamagnetic iron oxide-silica core with Au nanoshell for MRI (T2-weighted images).</td>
<td>91,124,125</td>
</tr>
<tr>
<td>siRNA-HAuNS</td>
<td>siRNA</td>
<td>Hollow nanospheres</td>
<td>40 nm</td>
<td>PET, PAT</td>
<td>PTT, radiotherapy</td>
<td>siRNA released by NIR irradiation through photothermal therapy.</td>
<td>91,126</td>
</tr>
<tr>
<td>AuNS@Fe₃O₄@SiO₂-ICG</td>
<td>HER2</td>
<td>Nanoshell</td>
<td>Silica core: 60 nm Au shell: 74 nm Fe₃O₄ nanoparticles: 10 nm Silica layer: 10 nm</td>
<td>Optical imaging, MRI</td>
<td>PTT</td>
<td>ICG on AuNS@Fe₃O₄@SiO₂ increases fluorescence of ICG. Conjugation with anti-HER2 targeted breast cancer cells.</td>
<td>127</td>
</tr>
<tr>
<td>Anti-HER2-AuNS@SiO₂</td>
<td>HER2</td>
<td>Nanoshell</td>
<td>Silica core: 120 nm Au shell thickness: 5–35 nm</td>
<td>OCT</td>
<td>PTT</td>
<td>Photothermal therapy induces cell death via nanoshell absorption of NIR light.</td>
<td>128</td>
</tr>
<tr>
<td>Anti-EGFR-AuNS</td>
<td>EGFR</td>
<td>Hollow nanoshell</td>
<td>35 nm</td>
<td>Optical imaging: TPL</td>
<td>PTT</td>
<td>Conjugation with anti-EGFR for targeting of cancer cells; cell death by photothermal therapy.</td>
<td>95,129</td>
</tr>
<tr>
<td>PEG-AuNR</td>
<td></td>
<td>Nanorods</td>
<td>47 nm × 13 nm (length/diameter)</td>
<td>X-ray CT</td>
<td>PTT</td>
<td>High X-ray absorption and spectral bandwithd. Single iv to destroy human xenograft tumor in mice.</td>
<td>27</td>
</tr>
<tr>
<td>siRNA-AuNR</td>
<td>siRNA</td>
<td>Nanorods</td>
<td>72 nm × 35 nm (length/diameter)</td>
<td>Light scattering</td>
<td>Gene therapy</td>
<td>Gene silencing.</td>
<td>82</td>
</tr>
<tr>
<td>Cisplatin@AuNR</td>
<td>Cisplatin</td>
<td>Nanorods</td>
<td>29.1 nm × 8.8 nm (length/diameter)</td>
<td>TEM</td>
<td>Thermal ablation, D</td>
<td>Higher cytotoxicity compared to free cisplatin.</td>
<td>130</td>
</tr>
<tr>
<td>DOX@AuNR</td>
<td>Doxorubicin, folate receptor</td>
<td>Nanorods</td>
<td>50 nm × 10 nm (length/diameter)</td>
<td>Cy3 luminescence</td>
<td>Thermo-chemotherapy, hyperthermia</td>
<td>Target cancer cells; drug release by hyperthermia promotes thermo-chemotherapy.</td>
<td>82,131</td>
</tr>
<tr>
<td>CET-PEG-AuNR</td>
<td>Cetuximab</td>
<td>Nanorods</td>
<td>Ratio (longitudinal/transverse): 4.0</td>
<td>Optical imaging</td>
<td>PTT</td>
<td>In vitro and in vivo application of CET-PEG-AuNR to NIR absorption imaging and photothermal therapy for epithelial carcinoma.</td>
<td>132</td>
</tr>
</tbody>
</table>
agents for a sustained, controlled, and targeted delivery of therapeutics coupled with the capability to follow in real-time distribution to tissues and organs, thus allowing therapy evaluation.63 These systems have been designed keeping in mind the selectivity for the most appropriate and effective therapy with fewer side effects.102,103 Despite the cumbersome task at hand, several nanosystems have been put forward for approval by the US Food and Drug Administration (FDA). Nanomedicines to make it to the market (worth US$33 billion) include Doxil® (Janssen Biotech) (Caelyx® in Europe), Myocet® (Spherion Therapeutics Inc, Princeton, NJ, USA), DaunoXome® (Galun US Inc, Souderton, PA, USA), DepoCyt® (Pacira Pharmaceuticals Inc, San Diego, CA, USA), Abraxane® (Celgene Corporation), Genexol-PM® (Samyang Biopharmaceuticals Corporation, Jongno-gu, Seoul, Korea), and Oncaspar® (Enzon Pharmaceuticals Inc, Bridgewater, NJ, USA).104

The overall nanomedicine market was evaluated in US$53 billion (2009) and is expected to be worth a staggering $100 billion in 2014.105 Several other FDA-approved nanomedicines have since reached the market, the last one to be Marqibo® (Spectrum Pharmaceuticals, Irvine, CA, USA) (FDA approval in 2012), which consists of a vincristine sulfate liposome injection for treatment of adult patients with Philadelphia chromosome–negative (Ph-) acute lymphoblastic leukemia in second or greater relapse or patients whose disease has still progressed despite two or more antileukemia therapies. Magnetic NPs are also making their way to clinical trials, and some formulations have been clinically approved for therapeutic applications and imaging (eg, Feridex® IV and Endorem® [Bayer Healthcare Pharmaceuticals] for liver and spleen imaging, Lumirens® (Guerbet SA, Villepinte, France) and Gastromark® (Advanced Magnetics Inc, Rochester, IN, USA) for bowel imaging).106 NanoTherm® (Magforce AG, Berlin, Germany), licenced in Europe since 2010 for the treatment of brain tumors, is an iron oxide NP administered to provide hyperthermia treatment localized to a tumor, sparing adjacent healthy tissue.107 A recent report shows that 247 nanomedicine products are approved or are in various stages of clinical study.108 Several more nanomedicines are to receive regulatory approval, but not all nanomedicines are available to the consumer.109 Almost 200 patents regarding NP-based drug delivery systems were registered between 2009 and 2012 in the World Intellectual Property Organization (WIPO), clearly indicating that these nanosystems may actually compete with conventional pharmaceuticals in the future.110

The ultimate goal in the R&D of a nanomedicine is its successful translation from bench to bedside. As mentioned...
earlier, there are still significant challenges, such as 1) scalability, 2) batch-to-batch reproducibility, 3) lack of complete information concerning the interaction between nanotheranostics and tissues (in vivo – eg, internalization and biodistribution), 4) effective increase of therapeutic indexes, 5) reluctance of the pharmaceutical industry to invest in nanotheranostics, 6) regulatory issues and safety guidelines from authorities and agencies (eg, FDA and European Medicines Agency [EMA]) that have to be addressed before nanotheranostics exert their full impact on the clinics. The health benefits of nanotheranostics structures depend on their reproducibility and mostly differentiation from available products concerning improved efficacy, safety, and pharmacokinetics. Among these issues, research still needs to fully address nanotoxicology, in particular effects arising from the chronic administration. Furthermore, nanomedicine regulation still presents gaps, such as standardization, safety, and risk guidelines. Several key points need to be addressed in the near future before widespread use of nanomaterials, and nanotheranostics in particular: reference nanomaterials; uniformity of standards for and/or working definitions of nanomaterials; improvement to the current definitions of nanomaterial, for the purpose of regulation (namely, the difference between nanomaterial and nanoscale material); development of toxicology tests and physicochemical characterization studies for nanomaterials. These issues are key to ensure that nanomedicines and nanotheranostics platforms do not face commercialization bottlenecks due to lack of standards and parameters that support rational preclinical characterization. Nevertheless, FDA, in accordance with the Nanotechnology Characterization Laboratory (NCL), is gathering relevant information for the resolutions of some of the issues mentioned earlier. And EMA is ready to follow suit. By the conduction of transitional studies that will help nanomedicine developers to bring their academic work to the market, NCL gained the knowhow on which approaches are most effective in characterizing the properties of nanomedicines. For instance, NCL established more than 40 protocols to characterize NPs’ physicochemical properties, in vitro immunogenicity, and cytotoxicity, together with the standard absorption, distribution, metabolism, excretion, and toxicity profiles, using animal models. Most of the reports available in the literature fail to deliver data on in vivo evaluation of nanomedicines and of nanotheranostic materials in particular. Existing data refer either to therapeutics or to diagnostics, leaving theranostics outside the scope of detailed testing.

**Final remarks**

The use of nanomaterials for biosensing and diagnostics is making its way into the clinics, and industry is grasping the novelty and the amazing performance provided by these platforms and strategies to boost their market position. In what therapeutics is concerned, nanomedicines are entering a decisive phase of clinical trials, and plenty of nanoformulations and radical strategies and delivery platforms will not make through the strenuous process of validation and certification before settling into the clinical setting. What is more, these new nanoscale formulations have been strongly focused on anticancer therapeutics, where the risk-to-gain ratio clearly favors the development and assessment of nanomaterials.

Nanotheranostics is following these two vectors of development very close, taking advantage of hurdles and obstacles removed by the isolated counterparts. One should note that nanotheranostics is more than the addition of parts; a synergy between diagnostics and therapeutics is in place that could not be attained via the isolated effect of either strategy. Perhaps because of this great advantage, validation and characterization are even more complex and are still waiting for suitable tools to ascertain the real value in the clinics. Nanotheranostics is moving forward fast and focused, and one ought to be ready to make the best of these powerful tools in the coming years.

**Acknowledgments**

We acknowledge Fundação para a Ciência e a Tecnologia (FCT- MCE) for financial support CIGMH (PEst-OE/SAU/UI0009/2011) and Project PTDC/BBB-NAN/1812/2012.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


